-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Why Is Virpax Pharmaceuticals (VRPX) Stock Up 97% Today?
Virpax Pharmaceuticals stock is up on Monday as VRPX investors react to new funding and changes to the company's board of directors.
3 Undervalued Stocks on Track to Double (or More) by 2028
The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028.
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Why Is Morphic (MORF) Stock Up 75% Today?
Morphic stock is up on Monday after the company signed a deal with Eli Lilly for the acquisition of MORF shares at $57 each in cash.
3 Breakthrough Medical Device Stocks to Invest In Now
Uncover the potential of leading medical device stocks boasting solid fundamentals and a promising future ahead.
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?
Qualigen Therapeutics stock is down on Monday after shares of QLGN experienced an unexpected rally with heavy trading on Friday.
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.
7 F-Rated Stocks To Sell in July
If you're going to outperform even a basic index fund this year, you need to identify any F-rated stocks to sell in July.
3 Defensive Stocks to Buy During the Market Dip
Clearway, Bristol-Myers Squibb and Universal Corp. are defensive stocks to buy on the dip, offering stable dividends and significant upside.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
3 Bargain Stocks With the Potential for Mind-Boggling Returns
Discover three bargain stocks leading in healthcare and pharmaceuticals with fundamentals behind their potential for massive returns.
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
7 Small-Cap Stocks With Massive Potential Returns
Having a list of small-cap stocks with high growth potential is similar to uncovering hidden gems.
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
Discover three high-potential penny stocks that could derive 10X returns in biotechnology, silver and oil and gas storage and transportation.
The 3 Best Biotech Stocks to Buy in July 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
3 Under-$10 Stocks With the Potential to Make You a Millionaire
Buying stocks under $10 might be one of the best ways to breach that million mark. Take a look at these three potential candidates.
